Holen Sie sich die Stockscreener-App
1.89
1.61%
0.03
Handel nachbörslich:
1.82
-0.07
-3.70%
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Clearmind Medicine (CMND) Holds Near $1.86 as Biotech Stock Consolidates Within Key RangeDouble EMA - dars.gov.et
Why Did CMND Stock Jump 40% Today? - Stocktwits
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial - Benzinga
Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder - Quiver Quantitative
Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc. (NASDAQ:CMND) - intelligentinvestor.com.au
Clearmind Medicine (CMND) holders report 9.99% cap on warrant-based stake - Stock Titan
Clearmind Medicine (CMND) reports intranasal MEAI permeation near 98% in study - Stock Titan
Clearmind Medicine Announces Positive Permeation Results For Intranasal Meai Formulation - TradingView
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery - The Manila Times
Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Program - Quiver Quantitative
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, ... - Enidnews.com
Clearmind’s nasal MEAI stays longer on tissue with comparable drug transport - Stock Titan
Clearmind Medicine (Nasdaq: CMND) wins DSMB nod to advance AUD trial - Stock Titan
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study - The Manila Times
CMND-100 Set to Enter Human Testing for Moderate-to-Severe Alcohol Use Disorder - Stock Titan
Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout - Bitget
Clearmind Medicine to acquire 51% stake in EV charging firm By Investing.com - Investing.com Nigeria
Clearmind Medicine Signs Letter Of Intent To Acquire 51% Majority Stake In Ev Wireless Charging Solutions For Automated Parking Systems Company - TradingView
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company - The Manila Times
Clearmind Medicine (Nasdaq: CMND) signs LOI for 51% EV charging stake - Stock Titan
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial - The Manila Times
Clearmind completes Part A of FDA-regulated tri... - Pluang
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - The Manila Times
Clearmind Medicine Completes Treatment of All Participants in Part A of Phase I/II AUD Trial for CMND-100 - Quiver Quantitative
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - GlobeNewswire Inc.
24 Participants Complete Treatment in Clearmind's Alcohol Use Disorder Trial - Stock Titan
Clearmind Medicine Inc (CMND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearmind Medicine Inc. Revenue Breakdown – FWB:CWY0 - TradingView
Clearmind Medicine Inc (CMND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Clearmind Medicine Inc (CMND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearmind Medicine Inc (CMND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CMND|Clearmind Medicine Inc|Price:1.628|Chg%:+0.018 - TradingKey
CMND|Clearmind Medicine Inc|Price:1.615|Chg%:-0.045 - TradingKey
Clearmind Medicine Inc (CMND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clearmind Medicine Inc (CMND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clearmind Medicine (CMND) Holds Near Support After Marginal DeclineLeveraged ETF Flow - dars.gov.et
Clearmind Medicine (CMND) Stock Forecast & Analyst Ratings - Moomoo
Clearmind Medicine Inc. (CMND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Clearmind files Hong Kong patent for PTSD treatment compounds - Investing.com
Clearmind Medicine Files Hong Kong Patent Application for PTSD-Targeting Compounds - Quiver Quantitative
Clearmind's PTSD Filing Targets Market Projected at $30.2B - Stock Titan
Clearmind submits addiction treatment proposal to U.S. HHS By Investing.com - Investing.com Nigeria
Clearmind Medicine Expends Global IP Portfolio With Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‐Billion‐Dollar PTSD Therapeutics Market - Moomoo
Clearmind Medicine comments on federal psychedelic guidance By Investing.com - Investing.com South Africa
Clearmind Medicine comments on federal psychedelic guidance - Investing.com UK
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction - The Manila Times
Clearmind reports mucoadhesion results for intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Reports Improved Mucoadhesion for Intranasal MEAI Formulation in Ex Vivo Study - Quiver Quantitative
Clearmind's MEAI formulation stayed longer on nasal tissue in testing - Stock Titan
Clearmind Medicine Inc. sees price surge amid market decline - Intellectia AI
Clearmind shares CMND-100 trial insights - grafa.com
Clearmind reports positive early data from alcohol disorder trial - Investing.com UK
Clearmind reports positive early data from alcohol disorder trial By Investing.com - Investing.com Canada
Clearmind's trial shows promising safety and po... - Pluang
Clearmind Medicine Reports Positive Early Experience in Phase I/IIa Trial of Non-Hallucinogenic MEAI for Alcohol Use Disorder - Quiver Quantitative
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Yahoo Finance Singapore
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):